Physician profile
Mark S Fedder
NPI 1922009943
$2,808.46
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $314 · 2020: $53.32 · 2021: $46.77 · 2022: $525 · 2023: $1,809 · 2024: $59.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,733 · Education: $136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,733.01 |
| Education | $135.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $833.01 | 2019-2024 | |
| Janssen Biotech, INC. | $673.26 | 2021-2024 | Stelara |
| Pfizer INC. | $218.12 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $202.91 | 2021-2023 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $178.66 | 2022-2023 | Xifaxan |
| Merck Sharp & Dohme LLC | $112.58 | 2022-2023 | Dificid |
| Qol Medical, LLC | $107.98 | 2023 | Sucraid |
| Braintree Laboratories, INC. | $83.40 | 2020-2023 | Sutab |
| Celgene Corporation | $75.65 | 2022-2023 | Zeposia |
| Genzyme Corporation | $65.72 | 2023 | |
| Scilex Pharmaceuticals INC. | $48.99 | 2019 | |
| Intercept Pharmaceuticals, INC. | $42.24 | 2023 | Ocaliva |
| Kaleo, INC. | $37.80 | 2019 | |
| Ferring Pharmaceuticals INC. | $34.15 | 2023 | Rebyota |
| Nestle Healthcare Nutrition INC. | $28.03 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $24.49 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $23.46 | 2022 | |
| Amgen INC. | $18.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Fedder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.